The company has planned to launch Favipiravir-200 mg tablets, recommended for the treatment of mild to moderate COVID-19 patients.
The shares of Jenburkt Pharmaceuticals climbed by over 10% during Tuesdays trading session after the company reported that its board wi
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity